Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N
Division of Thoracic Disease, Tochigi Cancer Center, Utsunomiya, Japan.
Cancer Chemother Pharmacol. 1990;26(6):389-92. doi: 10.1007/BF02994086.
cis-Diamminedichloroplatinum(II) (CDDP) was given as a single agent at a dose of 25 mg/m2 daily for 5 days by continuous infusion; treatment was repeated every 4 weeks in 30 previously untreated patients with advanced non-small-cell lung cancer (NSCLC). The median age of the patients was 61 years; 13 patients had limited disease and 17, extensive disease. The overall response rate was 40% (12/30; 95% confidence limits, 23-58%), with a median survival of 8 months. Vomiting was observed in 37% of patients; elevated serum creatinine levels (greater than 1.5 mg/dl), in 7%; leukopenia (less than 3,000/mm3), in 39%; thrombocytopenia (less than 70,000/mm3), in 26%; and anemia (hemoglobin less than 9.5 g/dl), in 60% of patients. In all cases, these toxicities were mild and transient, requiring no dose modification. The exposure to filterable platinum, determined from the area under the concentration-time curve, was 9.08 +/- 3.21 micrograms h ml-1. We conclude that CDDP given by 5-day continuous i.v. infusion is safe and effective for treatment of NSCLC.
顺二氯二氨铂（II）（CDDP）作为单一药物，以25mg/m²的剂量连续输注，每日一次，共5天；30例先前未接受过治疗的晚期非小细胞肺癌（NSCLC）患者每4周重复进行一次治疗。患者的中位年龄为61岁；13例患者疾病局限，17例患者疾病广泛。总缓解率为40%（12/30；95%置信区间，23-58%），中位生存期为8个月。37%的患者出现呕吐；7%的患者血清肌酐水平升高（大于1.5mg/dl）；39%的患者出现白细胞减少（低于3000/mm³）；26%的患者出现血小板减少（低于70000/mm³）；60%的患者出现贫血（血红蛋白低于9.5g/dl）。在所有病例中，这些毒性均为轻度且短暂，无需调整剂量。根据浓度-时间曲线下面积确定的可滤过铂暴露量为9.08±3.21μg h ml⁻¹。我们得出结论，5天连续静脉输注CDDP治疗NSCLC是安全有效的。
